As MannKind spends precious cash, it moves closer to the next capital raise (a.k.
RBC Capital’s Randall Stanicky says everything rides on Teva’s power to keep a grip on 2020 revenue.
Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) announced that the U.
Shares of Zosano Pharma Corp (NASDAQ:ZSAN) are rising nearly 13% in Friday’s trading session. The reason is nothing short of shocking.
BTIG’s Tim Chiang says Synergy has a “differentiated product” on its hands compared to the current winning market player: Ironwood/Allergan’s Linzess.
Canaccord’s John Newman finds SGYP’s Trulance commercial potential enticing down the line against its competitors.
Goldman Sachs’ Dana Flanders sheds new insights on Valeant from a bearish standpoint, spotting 5% in loss potential for the stock.
Now that SGYP has won over FDA approval in a new indication (IBS-C), did the biotech company’s competitive edge just get sharper?
Cowen’s Chris Shibutani is out downgrading and cutting his price target on PUMA stock, now seeing a mere 2% in upside potential.
A European approval seems unlikely.
